{"id":"NCT02318602","sponsor":"INSYS Therapeutics Inc","briefTitle":"Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder","officialTitle":"A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-01-08","primaryCompletion":"2017-06-22","completion":"2017-06-22","firstPosted":"2014-12-17","resultsPosted":"2018-07-26","lastUpdate":"2018-07-26"},"enrollment":52,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Seizures"],"interventions":[{"type":"DRUG","name":"Cannabidiol Oral Solution","otherNames":[]}],"arms":[{"label":"Infants","type":"EXPERIMENTAL"},{"label":"Children","type":"EXPERIMENTAL"},{"label":"Adolescents","type":"EXPERIMENTAL"}],"summary":"This is a multicenter, open-label trial to assess the long-term safety and efficacy of Cannabidiol Oral Solution as adjunctive therapy for pediatric participants with treatment-resistant seizure disorders, including Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS). All participants have rolled over from previous trials: INS011-14-029 (NCT02324673) and INS011-15-054 (NCT02551731).","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events","timeFrame":"Up to Week 50","effectByArm":[{"arm":"Infants","deltaMin":88.9,"sd":null},{"arm":"Children","deltaMin":92.3,"sd":null},{"arm":"Adolescents","deltaMin":88.2,"sd":null},{"arm":"All Participants","deltaMin":90.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":11,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":9},"commonTop":["Seizure","Upper respiratory tract infection","Somnolence","Diarrhoea","Pyrexia"]}}